Atrinsic (NASDAQ:PTIX) Trading 6.2% Higher – Still a Buy?

Atrinsic Inc. (NASDAQ:PTIX) traded up 6.2% during mid-day trading on Thursday . The company traded as high as $0.6583 and last traded at $0.6583. 34,356 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 549,151 shares. The stock had previously closed at $0.62.

Wall Street Analyst Weigh In

Several equities analysts have commented on PTIX shares. Wall Street Zen raised shares of Atrinsic from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Weiss Ratings reiterated a “sell (e)” rating on shares of Atrinsic in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Atrinsic presently has an average rating of “Sell”.

Atrinsic Trading Down 5.5%

The firm has a 50-day moving average of $1.63 and a two-hundred day moving average of $2.75. The firm has a market cap of $1.20 million, a price-to-earnings ratio of -0.08 and a beta of 0.51.

Atrinsic (NASDAQ:PTIX) last released its earnings results on Wednesday, November 26th. The company reported ($0.47) earnings per share (EPS) for the quarter.

About Atrinsic

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc is headquartered in New York, New York.